Drug Profile
MTLH 001
Alternative Names: MTLH-001; Platelet derived growth factor receptor antagonist - BeyondSpring PharmaceuticalLatest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Wuxi MTLH Biotechnology
- Developer BeyondSpring Pharmaceuticals; Shanghai Pharmaceutical Group
- Class Antineoplastics; Peptides
- Mechanism of Action Platelet-derived growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Cancer in China (unspecified route) (BeyondSpring Pharmaceuticals pipeline, August 2023)
- 29 Aug 2023 Discontinued - Preclinical for Cancer in USA (unspecified route) (BeyondSpring Pharmaceuticals pipeline, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Cancer in USA